Researchers have discovered that a molecule called nicotinamide, a component of vitamin B3 (niacin), binds to a sirtuin protein and prevents it from unleashing its renowned anti-aging effects.
A drug that prevents the niacin-sirtuin interaction could therefore help counteract age-related disorders, including obesity and type 2 diabetes.
Two Massachusetts-based companies are already working to develop drugs that affect sirtuin activity. Elixir Pharmaceuticals has filed more than 20 patents or applications related to a sirtuin class of compounds.